Catalyst Pharmaceuticals, Inc.
13 clinical trials · Sponsor
◉ Watch Catalyst Pharmaceuticals, Inc.
| Record | Firm | Date |
|---|---|---|
| Long Term Safety of Amifampridine Phosphate in Spinal Muscular Atrophy 3 (NCT03819660) | Catalyst Pharmaceuticals, Inc. | 2019-03-07 |
| Controlled Trial to Evaluate Amifampridine Phosphate in Spinal Muscular Atrophy Type 3 Patients (NCT03781479) | Catalyst Pharmaceuticals, Inc. | 2019-01-21 |
| Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis) (NCT03579966) | Catalyst Pharmaceuticals, Inc. | 2018-06-11 |
| Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG (NCT03304054) | Catalyst Pharmaceuticals, Inc. | 2018-04-18 |
Track Catalyst Pharmaceuticals, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.